Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Entrectinib Polymorph Forms A and C
NCT03796013Phase 1Completed
- Sponsor
- Genentech
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of entrectinib in solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Genentech. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration and Maximum Observed Concentration. Started Jan 2019; status: completed.
02
Drugs
entrectinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03796013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796013.